RUNX1 is a member of the core-binding factor family of transcription factors and is
indispensable for the establishment of definitive hematopoiesis in vertebrates. RUNX1 is …

Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …

Background Myelodysplastic syndromes are clinically heterogeneous disorders
characterized by clonal hematopoiesis, impaired differentiation, peripheral-blood …

Background The myelodysplastic syndromes are a group of hematologic disorders that often
evolve into secondary acute myeloid leukemia (AML). The genetic changes that underlie …

Although next-generation sequencing has allowed for the detection of somatic mutations in
myelodysplastic syndromes (MDS), the clinical relevance of variant allele frequency (VAF) …

The studies concerning clinical implications of TET2 mutation in patients with primary acute
myeloid leukemia (AML) are scarce. We analyzed TET2 mutation in 486 adult patients with …

Purpose To determine the association of RUNX1 mutations with therapeutic outcome in
younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN …

We evaluated the frequency, genetic architecture, clinico-pathologic features and prognostic
impact of RUNX1 mutations in 2439 adult patients with newly-diagnosed acute myeloid …

Somatically acquired genetic abnormalities lead to the salient features that define
myelodysplastic syndromes (MDS): clonal hematopoiesis, aberrant differentiation …

Somatic mutation of the AML1/RUNX1 (RUNX1) gene is seen in acute myeloid leukemia
(AML) M0 subtype and in AML transformed from myelodysplastic syndrome, but the impact …